Ascendis Pharma (ASND) return on invested capital (ROIC)

Return on invested capital · fiscal 2025
-115.9%

Ascendis Pharma (ASND) earned a return on invested capital of -115.9% in fiscal 2025 (the year ended December 31, 2025). That is 0.8 percentage points lower than the -115.1% of fiscal 2024. Figures as of 17 Nov 2026, 22:25 UTC, from Yahoo Finance.

Key facts

Return on invested capital, fiscal 2025
-115.9%
Change on fiscal 2024
−0.8 pts
Highest on record
-115.1%fiscal 2024
Lowest on record
-1223.7%fiscal 2022
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Ascendis Pharma return on invested capital (ROIC), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was -115.1% in fiscal 2024 and the lowest -1223.7% in fiscal 2022. The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is -363.0%.

History · 4 fiscal years

Return on invested capital by fiscal year

Ascendis Pharma return on invested capital (ROIC), year by year

Ascendis Pharma (ASND) return on invested capital (ROIC) by fiscal year
Fiscal yearReturn on invested capitalChangeYear ended
2025-115.9% 0.8 pts down
2024-115.1% 248.0 pts up
2023-363.0% 860.7 pts up
2022-1223.7%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

How to read it

It measures how well the business turns capital into profit whoever supplied it; a figure above the cost of that capital, roughly 8–10%, means growth creates value.

Return on invested capital at health care companies of similar size

Return on invested capital of Ascendis Pharma and comparable companies
CompanyReturn on invested capitalFiscal year
Revvity RVTY3.3%2025
Exelixis EXEL58.2%2025
Charles River Laboratories International CRL5.7%2025
Neurocrine Biosciences NBIX19.7%2025
Ascendis Pharma ASND-115.9%2025
ICON ICLR7.6%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ASND

Ascendis Pharma, figure by figure

Ascendis Pharma (ASND) overview: price, valuation and scorecardAll health care companies by market value

Ascendis Pharma return on invested capital (ROIC): questions and answers

What is Ascendis Pharma's return on invested capital?

Ascendis Pharma (ASND) earned a return on invested capital of -115.9% in fiscal 2025 (the year ended December 31, 2025). That is 0.8 percentage points lower than the -115.1% of fiscal 2024.

Is Ascendis Pharma's return on invested capital high or low compared with its own history?

The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is -363.0%.

What are the highest and lowest return on invested capital figures on record for Ascendis Pharma?

Across the 4 fiscal years on record (2022–2025), the highest was -115.1% in fiscal 2024 and the lowest -1223.7% in fiscal 2022.

How is Ascendis Pharma's return on invested capital calculated?

Return on invested capital is operating income after tax divided by the capital in the business — debt plus equity minus cash — using the company's own tax rate where it is plausible and 21% otherwise, and shown only for the fiscal years in which cash is counted one way.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Ascendis Pharma (ASND) return on invested capital (ROIC)”, data as of 17 November 2026. https://funkfolio.com/stock/ASND/roic

Underlying data: Yahoo Finance.